| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3293088 | Gastroenterology | 2012 | 16 Pages |
Abstract
The CC polymorphism at IL-28B rs12979860 is associated with response to triple therapy and can identify candidates for shorter treatment durations. A â¥1 log10 decrease in HCV RNA at week 4 of therapy is the strongest predictor of a SVR, regardless of polymorphisms in IL-28B. ClinicalTrials.gov; numbers NCT00705432 and NCT00708500.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Fred Poordad, Jean-Pierre Bronowicki, Stuart C. Gordon, Stefan Zeuzem, Ira M. Jacobson, Mark S. Sulkowski, Thierry Poynard, Timothy R. Morgan, Cliona Molony, Lisa D. Pedicone, Heather L. Sings, Margaret H. Burroughs, Vilma Sniukiene, Navdeep Boparai,